Lanreotide 120 mg every 28 days (LAN) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (panNET) in routine clinical practice in Iberia

被引：0

作者：

Alonso-Gordoa, T. ^{[1
]}

Capdevila, J. ^{[2
]}

Gonzalez, E. ^{[3
]}

Teule, A. ^{[4
]}

Anido, U. ^{[5
]}

Segura, A. ^{[6
]}

Bolanos, M. ^{[7
]}

Hernando, J. ^{[2
]}

Lorenzo, I ^{[8
]}

Grandoulier, A. S. ^{[9
]}

de La Cruz, G. ^{[10
]}

机构：

[1] Hosp Univ Ramon y Cajal, Madrid, Spain

[2] Hosp Univ Vall dHebron, Barcelona, Spain

[3] Hosp Univ Virgen de las Nieves, Granada, Spain

[4] Hosp ICO Bellvitge, Barcelona, Spain

[5] Hosp Prov Conxo, Santiago De Compostela, Spain

[6] Hosp Univ & Politecn La Fe, Valencia, Spain

[7] Hosp Univ Juan Ramon Jimenez, Huelva, Spain

[8] Hosp Alvaro Cunqueiro, Vigo, Spain

[9] Ipsen Pharma, Boulogne, France

[10] Ipsen Pharma, Barcelona, Spain

来源：

关键词：

net; pancreas; lanreotide; clinical practice;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

I02

引用

页码：164 / 164

页数：1